ONY Infasurf - Treat Respiratory Distress Syndrome in Newborns
First breath. First steps. First day of school. Since its FDA approval in 1998, ONY Biotech has made tomorrow possible for so many premature babies and their families, thanks to Infasurf®(calfactant). ONY Biotech’s primary commercial product, Infasurf®(calfactant), helps prevent and treat respiratory distress syndrome in newborns, restoring surface activity in the lungs and quickly improving respiration.
ONY Biotech is partnering with a start-up company formed by faculty in Chemical and Bioengineering at the University at Buffalo to develop acellular tissue engineered vessels (ATEV). Once implanted, the ATEV evolves over a few weeks into an anatomically and physiologically normal blood vessel populated by the recipient’s own cells. This technology may offer new options for vascular anomalies and diseases.
Working with a local company that specializes in gas detection technologies, ONY Biotech is developing a hand held hydrogen detection device. The 2nd generation device has demonstrated the ability to quickly and easily quantitate the hydrogen content in a premature baby’s breath. Hydrogen levels in expired air reflect the burden of hydrogen generating bacteria in the gastrointestinal tract. Monitoring gut bacteria load may be an additional tool to more effectively and safely manage alimentary feedings in small premature infants.
ONY Biotech is collaborating on scientific initiatives developed and implemented by academic scientists seeking new strategies to improve patients’ health. These projects range from the most basic laboratory research to clinical trials.